Bernstein Cuts Price Target on UnitedHealth Group to $337, Keeps "Outperform" Rating
PorAinvest
jueves, 7 de agosto de 2025, 11:52 pm ET1 min de lectura
BA--
Bernstein's decision to revise the price target is based on updated earnings estimates following UnitedHealth's Q2 2025 results. The company reported adjusted earnings per share of $4.08, down from the prior year, and revised its full-year guidance to at least $16 per share. UnitedHealth's CFO, John Rex, attributed the lower earnings to elevated medical costs, exchange-related headwinds, and slower growth in its OptumHealth division [2].
Despite the challenging environment, UnitedHealth remains optimistic about its long-term prospects. The company expects to return to earnings growth in 2026, driven by renewed focus on pricing, operational discipline, and long-term investments in AI and modernization. UnitedHealth also anticipates revenues of $445.5 billion to $448.0 billion and net earnings of at least $14.65 per share for 2025 [2].
The reduced price target reflects Bernstein's view that UnitedHealth's near-term earnings power may be lower than previously anticipated. However, the firm remains confident in the company's long-term growth prospects and the potential for earnings recovery in 2026 and beyond.
References:
[1] https://seekingalpha.com/article/4808332-unitedhealth-the-more-it-drops-the-more-ill-buy
[2] https://www.cfo.com/news/july-earnings-update-boeing-unitedhealth-starbucks-coca-cola-blackrock-/756977/
BLK--
KO--
SBUX--
UNH--
Bernstein reduced UnitedHealth Group's (UNH) price target to $337 from $377, while maintaining an "Outperform" rating. The firm reduced its estimates after Q2 2025 to reflect lower earnings power in 2025, but remains optimistic about the company's growth. UNH updated its 2025 outlook, expecting revenues of $445.5 billion - $448.0 billion and net earnings of at least $14.65 per share. The company anticipates returning to earnings growth in 2026.
UnitedHealth Group Incorporated (UNH) has faced a significant adjustment to its financial outlook, as Bernstein Research has reduced its price target for the healthcare giant. The firm lowered its price target from $377 to $337 while maintaining an "Outperform" rating. This decision follows Bernstein's reassessment of UNH's earnings power in 2025, which has been impacted by adverse medical cost trends and other headwinds.Bernstein's decision to revise the price target is based on updated earnings estimates following UnitedHealth's Q2 2025 results. The company reported adjusted earnings per share of $4.08, down from the prior year, and revised its full-year guidance to at least $16 per share. UnitedHealth's CFO, John Rex, attributed the lower earnings to elevated medical costs, exchange-related headwinds, and slower growth in its OptumHealth division [2].
Despite the challenging environment, UnitedHealth remains optimistic about its long-term prospects. The company expects to return to earnings growth in 2026, driven by renewed focus on pricing, operational discipline, and long-term investments in AI and modernization. UnitedHealth also anticipates revenues of $445.5 billion to $448.0 billion and net earnings of at least $14.65 per share for 2025 [2].
The reduced price target reflects Bernstein's view that UnitedHealth's near-term earnings power may be lower than previously anticipated. However, the firm remains confident in the company's long-term growth prospects and the potential for earnings recovery in 2026 and beyond.
References:
[1] https://seekingalpha.com/article/4808332-unitedhealth-the-more-it-drops-the-more-ill-buy
[2] https://www.cfo.com/news/july-earnings-update-boeing-unitedhealth-starbucks-coca-cola-blackrock-/756977/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios